Avantor Investor Conference Presentation Deck

2021 growth considerations Navantor™ $6.4B FY20E REVENUE SCENARIOS 1. Management estimates. 4% FY21E Low¹ 7% $7.0B $6.8B FY21E High¹ KEY VARIABLES Base lab utilization Vaccine and diagnostic trends Non-COVID-19 healthcare demand 39th Annual J.P. Morgan Healthcare Conference 20

View entire presentation